Skip to main content
Top

2020 | OriginalPaper | Chapter

10. How Should the United States Respond to the Opioid Addiction and Overdose Epidemic?

Authors : Keith Humphreys, Harold A. Pollack

Published in: The Palgrave Handbook of American Mental Health Policy

Publisher: Springer International Publishing

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

The national epidemic of addiction to and overdose from opioids is the worst public health crisis the United States has faced in decades. The health care system is critical to the public policy response, both because of the services it can provide people with opioid use disorder and the changes in clinical practice it must make to prevent new cases of addiction. For historical and cultural reasons, health services for people with opioid use disorder are often of uneven quality and poorly integrated with the rest of health care. However, effective services are available that can make a major contribution to pushing back against the epidemic. These include opioid agonist therapies (e.g., buprenorphine maintenance), antagonist therapies (e.g., extended-release naltrexone), and psychosocial treatments. Interventions that reduce the mortality and morbidity risks of opioids, such as syringe exchange and naloxone provision, are also critical to an effective public health response. Supply-side policies within the US health care system are also essential because overprescribing is at an extraordinarily high level both historically and currently in comparison to other nations. A range of monitoring, educational, and incentive-based interventions show promise of returning the United States to a more rational prescribing pattern.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literature
1.
go back to reference Ruhm, C. J. (2018). Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999–2015. Addiction, 113, 1339–1344.CrossRef Ruhm, C. J. (2018). Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999–2015. Addiction, 113, 1339–1344.CrossRef
3.
go back to reference Humphreys, K., Caulkins, J., & Felbab-Brown, V. (2018). Opioids of the masses: Stopping an American epidemic from going global. Foreign Affairs, 97, 118–129. Humphreys, K., Caulkins, J., & Felbab-Brown, V. (2018). Opioids of the masses: Stopping an American epidemic from going global. Foreign Affairs, 97, 118–129.
4.
go back to reference Buck, J. A. (2011). The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs, 20, 1402–1410.CrossRef Buck, J. A. (2011). The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affairs, 20, 1402–1410.CrossRef
5.
go back to reference Carson, E. A., & Anderson, E. (2016). Prisoners in 2015. Bureau of Justice Statistics Bulletin. United States Department of Justice. Carson, E. A., & Anderson, E. (2016). Prisoners in 2015. Bureau of Justice Statistics Bulletin. United States Department of Justice.
6.
go back to reference Patashnik, E. M., Gerber, A. A., & Dowling, C. M. (2017). Unhealthy politics: The battle over evidence-based medicine. Princeton: Princeton University Press.CrossRef Patashnik, E. M., Gerber, A. A., & Dowling, C. M. (2017). Unhealthy politics: The battle over evidence-based medicine. Princeton: Princeton University Press.CrossRef
7.
go back to reference White, W. L. (1998). Slaying the dragon: The history of addiction treatment and recovery in America. Bloomington, IL: Chestnut Health Systems. White, W. L. (1998). Slaying the dragon: The history of addiction treatment and recovery in America. Bloomington, IL: Chestnut Health Systems.
8.
go back to reference Humphreys, K. (2004). Circles of recovery: Self-help organisations for addictions. Cambridge, UK: Cambridge University Press. Humphreys, K. (2004). Circles of recovery: Self-help organisations for addictions. Cambridge, UK: Cambridge University Press.
9.
go back to reference Humphreys, K. (2017). How to deliver a more persuasive message regarding addiction as a medical disorder. Journal of Addiction Medicine, 11, 174–175.CrossRef Humphreys, K. (2017). How to deliver a more persuasive message regarding addiction as a medical disorder. Journal of Addiction Medicine, 11, 174–175.CrossRef
10.
go back to reference Humphreys, K., & Piot, P. (2012). Scientific evidence alone is not sufficient basis for health policy. British Medical Journal, 344, e1316.CrossRef Humphreys, K., & Piot, P. (2012). Scientific evidence alone is not sufficient basis for health policy. British Medical Journal, 344, e1316.CrossRef
11.
go back to reference Forman, J. J. (2017). Locking up our own: Crime and punishment in Black America. New York: Macmillan. Forman, J. J. (2017). Locking up our own: Crime and punishment in Black America. New York: Macmillan.
12.
go back to reference Massing, M. (2000). The fix. Berkeley: University of California Press. Massing, M. (2000). The fix. Berkeley: University of California Press.
13.
go back to reference Babor, T. F., Caulkins, J., Fischer, B., Foxcroft, D., Humphreys, K., Medina-Mora, M., … Strang, J. S. (2018). Drug policy and the public good (2nd ed.). London: Oxford University Press. Babor, T. F., Caulkins, J., Fischer, B., Foxcroft, D., Humphreys, K., Medina-Mora, M., … Strang, J. S. (2018). Drug policy and the public good (2nd ed.). London: Oxford University Press.
14.
go back to reference Dagan, D., & Teles, S. (2016). Prison break why conservatives turned against mass incarceration. Oxford: Oxford University Press. Dagan, D., & Teles, S. (2016). Prison break why conservatives turned against mass incarceration. Oxford: Oxford University Press.
20.
go back to reference Darke, S., & Zador, D. (1996). Fatal heroin “overdose”: A review. Addiction, 91, 1765–1772.CrossRef Darke, S., & Zador, D. (1996). Fatal heroin “overdose”: A review. Addiction, 91, 1765–1772.CrossRef
21.
go back to reference Sun, E. C., Dixit, A., Humphreys, K., Darnell, B., Baker, L. C., & Mackey, S. (2017). Association between concurrent use of prescription opioids and benzodiazepine with overdose: A retrospective analysis. British Medical Journal, 356, j760.CrossRef Sun, E. C., Dixit, A., Humphreys, K., Darnell, B., Baker, L. C., & Mackey, S. (2017). Association between concurrent use of prescription opioids and benzodiazepine with overdose: A retrospective analysis. British Medical Journal, 356, j760.CrossRef
22.
go back to reference Hall, W. D., & Strang, J. S. (2017). Alcohol problems need more attention in patients receiving long-term opioid substitution therapy. Lancet Psychiatry, 4, 265–266.CrossRef Hall, W. D., & Strang, J. S. (2017). Alcohol problems need more attention in patients receiving long-term opioid substitution therapy. Lancet Psychiatry, 4, 265–266.CrossRef
23.
go back to reference McLellan, A. T., Luborsky, L., Woody, G. E., O’Brien, C. P., & Kron, R. (1981). Are the “addiction-related” problems of substance abusers really related? Journal of Nervous and Mental Disease, 169, 232–239.CrossRef McLellan, A. T., Luborsky, L., Woody, G. E., O’Brien, C. P., & Kron, R. (1981). Are the “addiction-related” problems of substance abusers really related? Journal of Nervous and Mental Disease, 169, 232–239.CrossRef
24.
go back to reference Mbaba, M., Brown, S. E., Wooditch, A., Kiss, M., Murphy, A., Kumari, S., … Springer, S. A. (2018). Prevalence, diagnosis, and treatment rates of mood disorders among opioid users under criminal justice supervision. Substance Use & Misuse, 53, 1519–1528. Mbaba, M., Brown, S. E., Wooditch, A., Kiss, M., Murphy, A., Kumari, S., … Springer, S. A. (2018). Prevalence, diagnosis, and treatment rates of mood disorders among opioid users under criminal justice supervision. Substance Use & Misuse, 53, 1519–1528.
25.
go back to reference Humphreys, K., Malenka, R., Knutson, B., & MacCoun, R. (2017). Brains, environments and policy responses to addiction. Science, 356, 1237–1238.CrossRef Humphreys, K., Malenka, R., Knutson, B., & MacCoun, R. (2017). Brains, environments and policy responses to addiction. Science, 356, 1237–1238.CrossRef
27.
go back to reference Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S., & Gossop, M. (2003). Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. British Medical Journal, 326, 959–960. Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S., & Gossop, M. (2003). Loss of tolerance and overdose mortality after inpatient opiate detoxification: Follow up study. British Medical Journal, 326, 959–960.
28.
go back to reference Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison—A high risk of death for former inmates. New England Journal of Medicine, 356, 157–165. Binswanger, I. A., Stern, M. F., Deyo, R. A., Heagerty, P. J., Cheadle, A., Elmore, J. G., & Koepsell, T. D. (2007). Release from prison—A high risk of death for former inmates. New England Journal of Medicine, 356, 157–165.
29.
go back to reference Herman, D. B., & Mandiberg, J. M. (2010). Critical time intervention: Model description and implications for the significance of timing in social work interventions. Research on Social Work Practice, 20, 502–508.CrossRef Herman, D. B., & Mandiberg, J. M. (2010). Critical time intervention: Model description and implications for the significance of timing in social work interventions. Research on Social Work Practice, 20, 502–508.CrossRef
30.
go back to reference Green, T. C., Clarke, J., Brinkley-Rubinstein, L., Marshall, B. D. L., Alexander-Scott, N., Boss, R., & Rich, J. D. (2018, February 14). Post incarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2017.4614. Green, T. C., Clarke, J., Brinkley-Rubinstein, L., Marshall, B. D. L., Alexander-Scott, N., Boss, R., & Rich, J. D. (2018, February 14). Post incarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. https://​doi.​org/​10.​1001/​jamapsychiatry.​2017.​4614.
31.
go back to reference Carroll, K. M., & Weiss, R. D. (2017). The role of behavioral interventions in buprenorphine maintenance treatment: A review. American Journal of Psychiatry, 174, 738–747.CrossRef Carroll, K. M., & Weiss, R. D. (2017). The role of behavioral interventions in buprenorphine maintenance treatment: A review. American Journal of Psychiatry, 174, 738–747.CrossRef
32.
go back to reference Richardson, L., Wood, E., Li, K., & Kerr, T. (2010). Factors associated with employment among a cohort of injection drug users. Drug and Alcohol Review, 29, 293–300.CrossRef Richardson, L., Wood, E., Li, K., & Kerr, T. (2010). Factors associated with employment among a cohort of injection drug users. Drug and Alcohol Review, 29, 293–300.CrossRef
33.
go back to reference Fiellin, D. A., Kleber, H., Trumble-Hejduk, J. G., McLellan, A. T., & Kosten, T. R. (2004). Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment, 27(2), 153–159.CrossRef Fiellin, D. A., Kleber, H., Trumble-Hejduk, J. G., McLellan, A. T., & Kosten, T. R. (2004). Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment, 27(2), 153–159.CrossRef
36.
go back to reference World Health Organization. (2009). WHO guidelines for psychosocially assisted pharmacological treatment of persons dependent on opioids. Geneva, Switzerland: World Health Organization. World Health Organization. (2009). WHO guidelines for psychosocially assisted pharmacological treatment of persons dependent on opioids. Geneva, Switzerland: World Health Organization.
37.
go back to reference Amato, L., Davoli, M., Perucci, C. A., Ferri, M., Faggiano, F., & Mattick, R. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment, 28, 321–330.CrossRef Amato, L., Davoli, M., Perucci, C. A., Ferri, M., Faggiano, F., & Mattick, R. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment, 28, 321–330.CrossRef
38.
go back to reference Barnett, P. (1999). The cost-effectiveness of methadone maintenance as a health care intervention. Addiction, 94, 479–488.CrossRef Barnett, P. (1999). The cost-effectiveness of methadone maintenance as a health care intervention. Addiction, 94, 479–488.CrossRef
39.
go back to reference Gunne, L. M., & Grönbladh, L. (1981). The Swedish methadone maintenance program: A controlled study. Drug and Alcohol Dependence, 7, 249–256.CrossRef Gunne, L. M., & Grönbladh, L. (1981). The Swedish methadone maintenance program: A controlled study. Drug and Alcohol Dependence, 7, 249–256.CrossRef
40.
go back to reference Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., … Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. British Medical Journal, 357, j1550. Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., … Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. British Medical Journal, 357, j1550.
41.
go back to reference Basu, A., Paltiel, A. D., & Pollack, H. A. (2008). Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Economics, 17, 927–946.CrossRef Basu, A., Paltiel, A. D., & Pollack, H. A. (2008). Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Economics, 17, 927–946.CrossRef
42.
go back to reference Adi, Y., Juarez-Garcia, A., Wang, D., Jowett, S., Frew, E., Day, E., … Burls, A. (2007). Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation. Health Technology Assessment, 11, 1–85. Adi, Y., Juarez-Garcia, A., Wang, D., Jowett, S., Frew, E., Day, E., … Burls, A. (2007). Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: A systematic review and economic evaluation. Health Technology Assessment, 11, 1–85.
43.
go back to reference Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23, 63–75.CrossRef Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23, 63–75.CrossRef
44.
go back to reference Krupitsky, E., Zvartau, E., Blokhina, E., Verbitskaya, E., Wahlgren, V., Tsoy-Podosenin, M., … Woody, G. E. (2012). Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Archives of General Psychiatry, 69, 973–981. Krupitsky, E., Zvartau, E., Blokhina, E., Verbitskaya, E., Wahlgren, V., Tsoy-Podosenin, M., … Woody, G. E. (2012). Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Archives of General Psychiatry, 69, 973–981.
45.
go back to reference Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., … O’Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine, 374, 1232–1242. Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., … O’Brien, C. P. (2016). Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. New England Journal of Medicine, 374, 1232–1242.
46.
go back to reference Tanum, L., Solli, K. K., Latif, Z., Benth, J. S., Opheim, A., Sharma-Haase, K., … Kune, N. (2017). Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence. JAMA Psychiatry, 74, 1197–1205. Tanum, L., Solli, K. K., Latif, Z., Benth, J. S., Opheim, A., Sharma-Haase, K., … Kune, N. (2017). Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence. JAMA Psychiatry, 74, 1197–1205.
47.
go back to reference Prendergast, M. L., Podus, D., Chang, E., & Urada, D. (2002). The effectiveness of drug abuse treatment: A meta-analysis of comparison group studies. Drug and Alcohol Dependence, 67, 53–73.CrossRef Prendergast, M. L., Podus, D., Chang, E., & Urada, D. (2002). The effectiveness of drug abuse treatment: A meta-analysis of comparison group studies. Drug and Alcohol Dependence, 67, 53–73.CrossRef
48.
go back to reference Mayet, S., Farrell, M., Ferri, M., Amato, L., & Davoli, M. (2005, January 25). Psychosocial treatment for opiate abuse and dependence. Cochrane Database Systematic Review, 1, CD004330. Mayet, S., Farrell, M., Ferri, M., Amato, L., & Davoli, M. (2005, January 25). Psychosocial treatment for opiate abuse and dependence. Cochrane Database Systematic Review, 1, CD004330.
49.
go back to reference Butzin, C. A., Martin, S. S., & Inciardi, J. A. (2005). Treatment during transition from prison to community and subsequent illicit drug use. Journal of Substance Abuse Treatment, 28, 351–358.CrossRef Butzin, C. A., Martin, S. S., & Inciardi, J. A. (2005). Treatment during transition from prison to community and subsequent illicit drug use. Journal of Substance Abuse Treatment, 28, 351–358.CrossRef
50.
go back to reference Vanderplasschen, W., Colpaert, K., Autrique, M., Rapp, R., Pearce, A., Broekaert, E., & Vandevelde, S. (2013, January 15). Therapeutic communities for addictions: A review of their effectiveness from a recovery-oriented perspective. Scientific World Journal, 2013, 1–22. Vanderplasschen, W., Colpaert, K., Autrique, M., Rapp, R., Pearce, A., Broekaert, E., & Vandevelde, S. (2013, January 15). Therapeutic communities for addictions: A review of their effectiveness from a recovery-oriented perspective. Scientific World Journal, 2013, 1–22.
51.
go back to reference Babor, T. F., Caulkins, J., Edwards, G. E., Fischer, B., Foxcroft, D., Humphreys, K., … Strang, J. S. (2010). Drug policy and the public good. New York: Oxford University Press. Babor, T. F., Caulkins, J., Edwards, G. E., Fischer, B., Foxcroft, D., Humphreys, K., … Strang, J. S. (2010). Drug policy and the public good. New York: Oxford University Press.
52.
go back to reference Welsh, W. N., Zajac, G., & Bucklen, K. B. (2014). For whom does prison-based drug treatment work? Results from a randomized experiment. Journal of Experimental Criminology, 10, 151–177.CrossRef Welsh, W. N., Zajac, G., & Bucklen, K. B. (2014). For whom does prison-based drug treatment work? Results from a randomized experiment. Journal of Experimental Criminology, 10, 151–177.CrossRef
53.
go back to reference D’Aunno, T., & Pollack, H. A. (2002). Changes in methadone treatment practices: Results from a national panel study, 1988–2000. Journal of the American Medical Association, 288, 850–856.CrossRef D’Aunno, T., & Pollack, H. A. (2002). Changes in methadone treatment practices: Results from a national panel study, 1988–2000. Journal of the American Medical Association, 288, 850–856.CrossRef
54.
go back to reference White, W., Galanter, M., Humphreys, K., & Kelly, J. (2016). The paucity of attention to Narcotics Anonymous in current public, professional and policy responses to rising opioid addiction. Alcoholism Treatment Quarterly, 34, 437–462.CrossRef White, W., Galanter, M., Humphreys, K., & Kelly, J. (2016). The paucity of attention to Narcotics Anonymous in current public, professional and policy responses to rising opioid addiction. Alcoholism Treatment Quarterly, 34, 437–462.CrossRef
55.
go back to reference Jason, L. A., Olson, B. D., Ferrari, J. R., & Lo Sasso, L. T. (2006). Communal housing settings enhance substance abuse recovery. American Journal of Public Health, 96, 1727–1729.CrossRef Jason, L. A., Olson, B. D., Ferrari, J. R., & Lo Sasso, L. T. (2006). Communal housing settings enhance substance abuse recovery. American Journal of Public Health, 96, 1727–1729.CrossRef
56.
go back to reference Heimer, R. (1998). Can syringe exchange serve as a conduit to substance abuse treatment? Journal of Substance Abuse Treatment, 15, 183–191.CrossRef Heimer, R. (1998). Can syringe exchange serve as a conduit to substance abuse treatment? Journal of Substance Abuse Treatment, 15, 183–191.CrossRef
57.
go back to reference Pollack, H. A. (2001). Cost-effectiveness of harm reduction in preventing Hepatitis C among injection drug users. Medical Decision Making, 21, 357–367.CrossRef Pollack, H. A. (2001). Cost-effectiveness of harm reduction in preventing Hepatitis C among injection drug users. Medical Decision Making, 21, 357–367.CrossRef
58.
go back to reference Groseclose, S. L., Weinstein, B., Jones, T. S., Valleroy, L. A., Fehrs, L. J., & Kassler, W. (1995). Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officer, Connecticut, 1992–1993. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 10, 82–89.CrossRef Groseclose, S. L., Weinstein, B., Jones, T. S., Valleroy, L. A., Fehrs, L. J., & Kassler, W. (1995). Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officer, Connecticut, 1992–1993. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 10, 82–89.CrossRef
59.
go back to reference Humphreys, K. (2015). An overdose rescue drug goes mainstream. Health Affairs, 34, 1624–1627.CrossRef Humphreys, K. (2015). An overdose rescue drug goes mainstream. Health Affairs, 34, 1624–1627.CrossRef
60.
go back to reference Baca, C. T., & Grant, K. J. (2005). Take-home naloxone to reduce heroin death. Addiction, 100, 1823–1831.CrossRef Baca, C. T., & Grant, K. J. (2005). Take-home naloxone to reduce heroin death. Addiction, 100, 1823–1831.CrossRef
61.
go back to reference Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R. (1996). Heroin overdose: The case for take-home naloxone. British Medical Journal, 312, 1435–1436.CrossRef Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R. (1996). Heroin overdose: The case for take-home naloxone. British Medical Journal, 312, 1435–1436.CrossRef
62.
go back to reference Darke, S., & Hall, W. (1997). The distribution of naloxone to heroin users. Addiction, 92, 1195–1199.CrossRef Darke, S., & Hall, W. (1997). The distribution of naloxone to heroin users. Addiction, 92, 1195–1199.CrossRef
63.
go back to reference McDonald, R., & Strang, J. S. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction, 111, 1177–1187.CrossRef McDonald, R., & Strang, J. S. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction, 111, 1177–1187.CrossRef
64.
go back to reference Walley, A. Y., Xuan, Z., Hackman, H. H., et al. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. British Medical Journal, 346, f174. Walley, A. Y., Xuan, Z., Hackman, H. H., et al. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. British Medical Journal, 346, f174.
65.
go back to reference Williams, A. V., Marsden, J., & Strang, J. (2014). Training family members to manage heroin overdose and administer naloxone: Randomized trial of effects on knowledge and attitudes. Addiction, 109, 250–259.CrossRef Williams, A. V., Marsden, J., & Strang, J. (2014). Training family members to manage heroin overdose and administer naloxone: Randomized trial of effects on knowledge and attitudes. Addiction, 109, 250–259.CrossRef
66.
go back to reference Bashir, K., King, M., & Ashworth, M. (1994). Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. British Journal of General Practice, 44, 408–412. Bashir, K., King, M., & Ashworth, M. (1994). Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. British Journal of General Practice, 44, 408–412.
67.
go back to reference Cormack, M. A., Sweeney, K. G., Hughes-Jones, H., & Foot, G. A. (1994). Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. British Journal of General Practice, 44, 5–8. Cormack, M. A., Sweeney, K. G., Hughes-Jones, H., & Foot, G. A. (1994). Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice. British Journal of General Practice, 44, 5–8.
68.
go back to reference Tannenbaum, C., Martin, P., & Tamblin, R. (2014). Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER cluster randomized trial. JAMA Internal Medicine, 174, 890–898.CrossRef Tannenbaum, C., Martin, P., & Tamblin, R. (2014). Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER cluster randomized trial. JAMA Internal Medicine, 174, 890–898.CrossRef
69.
go back to reference Marsden, J., Stillwell, G., Barlow, H., Boys, A., Taylor, C., Hunt, N., & Farrell, M. (2005). An evaluation of a brief motivational intervention among young ecstasy and cocaine users: No effect on substance and alcohol use outcomes. Addiction, 101, 1014–1026. Marsden, J., Stillwell, G., Barlow, H., Boys, A., Taylor, C., Hunt, N., & Farrell, M. (2005). An evaluation of a brief motivational intervention among young ecstasy and cocaine users: No effect on substance and alcohol use outcomes. Addiction, 101, 1014–1026.
70.
go back to reference Baker, A., Lewin, T., Reichler, H., Clancy, R., Carr, V., Garrett, R., … Terry, M. (2002). Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction, 97, 1329–1337. Baker, A., Lewin, T., Reichler, H., Clancy, R., Carr, V., Garrett, R., … Terry, M. (2002). Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction, 97, 1329–1337.
71.
go back to reference Humphreys, K. (2017). Avoiding globalisation of the prescription opioid epidemic. The Lancet, 390, 437–439.CrossRef Humphreys, K. (2017). Avoiding globalisation of the prescription opioid epidemic. The Lancet, 390, 437–439.CrossRef
72.
go back to reference Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States. Morbidity and Mortality Weekly Report, 65, 1–49. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States. Morbidity and Mortality Weekly Report, 65, 1–49.
73.
go back to reference Lembke, A., Humphreys, K., & Newmark, J. (2016). Weighing the risks and benefits of chronic opioid therapy. American Family Physician, 93, 982–990. Lembke, A., Humphreys, K., & Newmark, J. (2016). Weighing the risks and benefits of chronic opioid therapy. American Family Physician, 93, 982–990.
74.
go back to reference Morris, L. A., & Halperin, J. A. (1979). Effects of written drug information on patient knowledge and compliance: A literature review. American Journal of Public Health, 69, 47–52.CrossRef Morris, L. A., & Halperin, J. A. (1979). Effects of written drug information on patient knowledge and compliance: A literature review. American Journal of Public Health, 69, 47–52.CrossRef
75.
go back to reference Peveler, R., George, C., Kinmonth, A. L., Campbell, M., & Thompson, C. (1999). Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: Randomised controlled trial. British Medical Journal (Clinical Research Ed.), 319, 612–615.CrossRef Peveler, R., George, C., Kinmonth, A. L., Campbell, M., & Thompson, C. (1999). Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: Randomised controlled trial. British Medical Journal (Clinical Research Ed.), 319, 612–615.CrossRef
76.
go back to reference Roughead, E. E., Semple, S. J., & Vitry, A. I. (2005). Pharmaceutical care services: A systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. International Journal of Pharmacy Practice, 13, 53–70.CrossRef Roughead, E. E., Semple, S. J., & Vitry, A. I. (2005). Pharmaceutical care services: A systematic review of published studies, 1990 to 2003, examining effectiveness in improving patient outcomes. International Journal of Pharmacy Practice, 13, 53–70.CrossRef
77.
go back to reference Schnipper, J. L., Kirwin, J. L., Cotugno, M. C., Wahlstrom, S. A., Brown, B. A., Tarvin, E., … Bates, D. W. (2006). Role of pharmacist counseling in preventing adverse drug events after hospitalization. Archives of Internal Medicine, 166, 565–571. Schnipper, J. L., Kirwin, J. L., Cotugno, M. C., Wahlstrom, S. A., Brown, B. A., Tarvin, E., … Bates, D. W. (2006). Role of pharmacist counseling in preventing adverse drug events after hospitalization. Archives of Internal Medicine, 166, 565–571.
78.
go back to reference Christensen, D. B., & Farris, K. B. (2006). Pharmaceutical care in community pharmacies: Practice and research in the US. The Annals of Pharmacotherapy, 40, 1400–1406.CrossRef Christensen, D. B., & Farris, K. B. (2006). Pharmaceutical care in community pharmacies: Practice and research in the US. The Annals of Pharmacotherapy, 40, 1400–1406.CrossRef
79.
go back to reference Betses, M., & Brennan, T. (2013). Abusive prescribing of controlled substances—A pharmacy view. New England Journal of Medicine, 369, 989–991.CrossRef Betses, M., & Brennan, T. (2013). Abusive prescribing of controlled substances—A pharmacy view. New England Journal of Medicine, 369, 989–991.CrossRef
80.
go back to reference Sacarny, A., Yokum, D., Finkelstein, A., & Agrawal, S. (2016). Medicare letters to curb overprescribing of controlled substances had no detectable effect on providers. Health Affairs, 35, 471–479.CrossRef Sacarny, A., Yokum, D., Finkelstein, A., & Agrawal, S. (2016). Medicare letters to curb overprescribing of controlled substances had no detectable effect on providers. Health Affairs, 35, 471–479.CrossRef
81.
go back to reference Aaserud, M., Dahlgren, A. T., Kosters, J. P., Oxman, A. D., Ramsay, C., & Sturm, H. (2006). Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. The Cochrane Database of Systematic Reviews, 2, CD005979. Aaserud, M., Dahlgren, A. T., Kosters, J. P., Oxman, A. D., Ramsay, C., & Sturm, H. (2006). Pharmaceutical policies: Effects of reference pricing, other pricing, and purchasing policies. The Cochrane Database of Systematic Reviews, 2, CD005979.
82.
go back to reference Cicero, T. J., Inciardi, J. A., Adams, E. H., Geller, A., Senay, E. C., Woody, G. E., & Munoz, A. (2005). Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994–2004. Pharmacoepidemiology and Drug Safety, 14, 851–859. Cicero, T. J., Inciardi, J. A., Adams, E. H., Geller, A., Senay, E. C., Woody, G. E., & Munoz, A. (2005). Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994–2004. Pharmacoepidemiology and Drug Safety, 14, 851–859.
83.
go back to reference Gomes, T., Mamdani, M. M., Dhalla, I. A., Cornish, S., Paterson, J. M., & Juurlink, D. N. (2014). The burden of premature opioid-related mortality. Addiction, 109, 1482–1488.CrossRef Gomes, T., Mamdani, M. M., Dhalla, I. A., Cornish, S., Paterson, J. M., & Juurlink, D. N. (2014). The burden of premature opioid-related mortality. Addiction, 109, 1482–1488.CrossRef
84.
go back to reference Fischer, B., & Keates, A. (2012). ‘Opioid drought’, Canadian-style? Potential implications of the ‘natural experiment’ of delisting Oxycontin in Canada. The International Journal on Drug Policy, 23, 495–497.CrossRef Fischer, B., & Keates, A. (2012). ‘Opioid drought’, Canadian-style? Potential implications of the ‘natural experiment’ of delisting Oxycontin in Canada. The International Journal on Drug Policy, 23, 495–497.CrossRef
85.
go back to reference Fischer, B., Jones, W., & Rehm, J. (2014). Trends and changes in prescription opioid analgesic dispensing in Canada 2005–2012: An update with a focus on recent interventions. BMC Health Services Research, 14, 90.CrossRef Fischer, B., Jones, W., & Rehm, J. (2014). Trends and changes in prescription opioid analgesic dispensing in Canada 2005–2012: An update with a focus on recent interventions. BMC Health Services Research, 14, 90.CrossRef
86.
go back to reference Faul, M., Bohm, M., & Alexander, C. (2017). Methadone prescribing and overdose an the association with Medicaid preferred drug list policies—United States, 2007–2014. Morbidity and Mortality Weekly Report, 66, 320–323.CrossRef Faul, M., Bohm, M., & Alexander, C. (2017). Methadone prescribing and overdose an the association with Medicaid preferred drug list policies—United States, 2007–2014. Morbidity and Mortality Weekly Report, 66, 320–323.CrossRef
87.
go back to reference Hall, A. J., Logan, J. E., Toblin, R. L., Kaplan, J. A., Kraner, J. C., Bixler, D., … Paulozzi, L. J. (2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. Journal American Medical Association, 300, 2613–2620. Hall, A. J., Logan, J. E., Toblin, R. L., Kaplan, J. A., Kraner, J. C., Bixler, D., … Paulozzi, L. J. (2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. Journal American Medical Association, 300, 2613–2620.
88.
go back to reference Roberts, A. W., & Skinner, A. C. (2014). Assessing the present state and potential of Medicaid controlled substance lock-in programs. Journal of Managed Care & Specialty Pharmacy, 20(5), 439–446.CrossRef Roberts, A. W., & Skinner, A. C. (2014). Assessing the present state and potential of Medicaid controlled substance lock-in programs. Journal of Managed Care & Specialty Pharmacy, 20(5), 439–446.CrossRef
89.
go back to reference Katz, N. P., Brennan, M. J., Freedman, J. D., Birnbaum, H., Gilmore, G. P., Jay, D., … White, A. G. (2013). Prescription opioid abuse: Challenges and opportunities for payers. American Journal of Managed Care, 19, 295–302. Katz, N. P., Brennan, M. J., Freedman, J. D., Birnbaum, H., Gilmore, G. P., Jay, D., … White, A. G. (2013). Prescription opioid abuse: Challenges and opportunities for payers. American Journal of Managed Care, 19, 295–302.
90.
go back to reference Franklin, G., Sabel, S., Jones, C. M., Mai, J., Baumgartner, C., Banta-Green, C. J., … Tauben, D. J. (2015). A comprehensive approach to address the prescription opioid epidemic in Washington State: Milestones and lessons learned. American Journal of Public Health, 105, 463–469. Franklin, G., Sabel, S., Jones, C. M., Mai, J., Baumgartner, C., Banta-Green, C. J., … Tauben, D. J. (2015). A comprehensive approach to address the prescription opioid epidemic in Washington State: Milestones and lessons learned. American Journal of Public Health, 105, 463–469.
91.
go back to reference Brennan, N., & Mattick, K. (2013). A systematic review of educational interventions to change behaviour of prescribers in hospital settings, with a particular emphasis on new prescribers. British Journal of Clinical Pharmacology, 75, 359–372.CrossRef Brennan, N., & Mattick, K. (2013). A systematic review of educational interventions to change behaviour of prescribers in hospital settings, with a particular emphasis on new prescribers. British Journal of Clinical Pharmacology, 75, 359–372.CrossRef
92.
go back to reference Franklin, G. M., Mai, J., Turner, J., Sullivan, M., Wickizer, T., & Fulton-Kehoe, D. (2012). Bending the prescription opioid dosing and mortality curves: Impact of the Washington state opioid dosing guideline. American Journal of Industrial Medicine, 55, 325–331.CrossRef Franklin, G. M., Mai, J., Turner, J., Sullivan, M., Wickizer, T., & Fulton-Kehoe, D. (2012). Bending the prescription opioid dosing and mortality curves: Impact of the Washington state opioid dosing guideline. American Journal of Industrial Medicine, 55, 325–331.CrossRef
93.
go back to reference Pimlott, N. J., Hux, J. E., Wilson, L. M., Kahan, M., Li, C., & Rosser, W. W. (2003). Educating physicians to reduce benzodiazepine use by elderly patients: A randomized controlled trial. CMAJ: Canadian Medical Association Journal [Journal De L’Association Medicale Canadienne], 168, 835–839. Pimlott, N. J., Hux, J. E., Wilson, L. M., Kahan, M., Li, C., & Rosser, W. W. (2003). Educating physicians to reduce benzodiazepine use by elderly patients: A randomized controlled trial. CMAJ: Canadian Medical Association Journal [Journal De L’Association Medicale Canadienne], 168, 835–839.
94.
go back to reference Hooper, S., Bruno, R., Sharpe, M., & Tahmindjis, A. (2009). Alprazolam prescribing in tasmania: A two-fold intervention designed to reduce inappropriate prescribing and concomitant opiate prescription. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists, 17, 300–305.CrossRef Hooper, S., Bruno, R., Sharpe, M., & Tahmindjis, A. (2009). Alprazolam prescribing in tasmania: A two-fold intervention designed to reduce inappropriate prescribing and concomitant opiate prescription. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists, 17, 300–305.CrossRef
95.
go back to reference Kahan, M., Gomes, T., Juurlink, D. N., Manno, M., Wilson, L., Mailis-Gagnon, A., … Mamdani, M. M. (2013). Effect of a course-based intervention and effect of medical regulation on physicians’ opioid prescribing. Canadian Family Physician, 59, 231–239. Kahan, M., Gomes, T., Juurlink, D. N., Manno, M., Wilson, L., Mailis-Gagnon, A., … Mamdani, M. M. (2013). Effect of a course-based intervention and effect of medical regulation on physicians’ opioid prescribing. Canadian Family Physician, 59, 231–239.
96.
go back to reference Parish, C. L., Pereyra, M. R., Pollack, H. A., Cardenas, G., Castellon, P. C., Abel, S. N., … Metsch, L. R. (2015). Screening for substance misuse in the dental care setting: Findings from a nationally representative survey of dentists. Addiction, 110, 1516–1523. Parish, C. L., Pereyra, M. R., Pollack, H. A., Cardenas, G., Castellon, P. C., Abel, S. N., … Metsch, L. R. (2015). Screening for substance misuse in the dental care setting: Findings from a nationally representative survey of dentists. Addiction, 110, 1516–1523.
98.
go back to reference Victorri-Vigneau, C., Basset, G., Bourin, M., & Jolliet, P. (2003). Impacts of the new flunitrazepam regulations on the consumption of hypnotics [Impacts de la nouvelle reglementation du flunitrazepam sur la consommation d’hypnotiques]. Therapie, 58(5), 425–430. Victorri-Vigneau, C., Basset, G., Bourin, M., & Jolliet, P. (2003). Impacts of the new flunitrazepam regulations on the consumption of hypnotics [Impacts de la nouvelle reglementation du flunitrazepam sur la consommation d’hypnotiques]. Therapie, 58(5), 425–430.
99.
go back to reference Jonasson, U., & Jonasson, B. (2004). Restrictions on the prescribing of dextropropoxyphene (DXP)-effects on sales and cases of fatal poisoning. Stockholm, Sweden: Swedish National Board of Forensic Medicine and Medical Products Agency. Jonasson, U., & Jonasson, B. (2004). Restrictions on the prescribing of dextropropoxyphene (DXP)-effects on sales and cases of fatal poisoning. Stockholm, Sweden: Swedish National Board of Forensic Medicine and Medical Products Agency.
100.
go back to reference Seago, S., Hayek, A., Pruszynski, J., & Newman, M. G. (2016). Change in prescription habits after federal rescheduling of hydrocodone combination products. Baylor University Medical Center Proceedings, 29, 268–270.CrossRef Seago, S., Hayek, A., Pruszynski, J., & Newman, M. G. (2016). Change in prescription habits after federal rescheduling of hydrocodone combination products. Baylor University Medical Center Proceedings, 29, 268–270.CrossRef
101.
go back to reference Jones, C. M., Lurie, P. G., & Throckmorton, D. C. (2016). Effect of US Drug Enforcement Administration’s rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Internal Medicine, 176, 399–402.CrossRef Jones, C. M., Lurie, P. G., & Throckmorton, D. C. (2016). Effect of US Drug Enforcement Administration’s rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Internal Medicine, 176, 399–402.CrossRef
102.
go back to reference Furlan, A. D., MacDougall, P., Pellerin, D., Shaw, K., Spitzig, D., Wilson, G., & Wright, J. (2014). Overview of four prescription monitoring/review programs in Canada. Pain Research & Management, 19, 102–106. Furlan, A. D., MacDougall, P., Pellerin, D., Shaw, K., Spitzig, D., Wilson, G., & Wright, J. (2014). Overview of four prescription monitoring/review programs in Canada. Pain Research & Management, 19, 102–106.
103.
go back to reference Katz, N., Houle, B., Fernandez, K., Kreiner, P., Thomas, C., Kim, M., … Brushwood, D. (2008). Update on prescription monitoring in clinical practice: A survey study of prescription monitoring program administrators. Pain Medicine, 9, 587–594. Katz, N., Houle, B., Fernandez, K., Kreiner, P., Thomas, C., Kim, M., … Brushwood, D. (2008). Update on prescription monitoring in clinical practice: A survey study of prescription monitoring program administrators. Pain Medicine, 9, 587–594.
104.
go back to reference Pardo, B. (2017). Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction, 112, 1773–1783.CrossRef Pardo, B. (2017). Do more robust prescription drug monitoring programs reduce prescription opioid overdose? Addiction, 112, 1773–1783.CrossRef
105.
go back to reference Moyo, P., Simoni-Wastila, L., Griffi, B. A., Harrington, D., Alexander, G. C., & Palumbo, F. (2017). Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 U.S. States. Addiction, 112, 1784–1796.CrossRef Moyo, P., Simoni-Wastila, L., Griffi, B. A., Harrington, D., Alexander, G. C., & Palumbo, F. (2017). Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 U.S. States. Addiction, 112, 1784–1796.CrossRef
106.
go back to reference Baehren, D. F., Marco, C. A., Droz, D. E., Sinha, S., Callan, E. M., & Akpunonu, P. (2010). A statewide prescription monitoring program affects emergency department prescribing behaviors. Annals of Emergency Medicine, 56, 19–23.CrossRef Baehren, D. F., Marco, C. A., Droz, D. E., Sinha, S., Callan, E. M., & Akpunonu, P. (2010). A statewide prescription monitoring program affects emergency department prescribing behaviors. Annals of Emergency Medicine, 56, 19–23.CrossRef
107.
go back to reference Dormuth, C. R., Miller, T. A., Huang, A., Mamdani, M. M., & Juurlink, D. N. (2012). Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. Canadian Medical Association Journal, 184, E852–E856.CrossRef Dormuth, C. R., Miller, T. A., Huang, A., Mamdani, M. M., & Juurlink, D. N. (2012). Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. Canadian Medical Association Journal, 184, E852–E856.CrossRef
108.
go back to reference Fishman, S. M., Papazian, J. S., Gonzalez, S., Riches, P. S., & Gilson, A. (2004). Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain. Pain Medicine, 5(3), 309–324.CrossRef Fishman, S. M., Papazian, J. S., Gonzalez, S., Riches, P. S., & Gilson, A. (2004). Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain. Pain Medicine, 5(3), 309–324.CrossRef
109.
go back to reference Gilson, A. M., Fishman, S. M., Wilsey, B. L., Casamalhuapa, C., & Baxi, H. (2012). Time series analysis of California’s prescription monitoring program: Impact on prescribing and multiple provider episodes. Journal of Pain, 13, 103–111.CrossRef Gilson, A. M., Fishman, S. M., Wilsey, B. L., Casamalhuapa, C., & Baxi, H. (2012). Time series analysis of California’s prescription monitoring program: Impact on prescribing and multiple provider episodes. Journal of Pain, 13, 103–111.CrossRef
110.
go back to reference Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016). Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs, 35, 1324–1332.CrossRef Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016). Implementation of prescription drug monitoring programs associated with reductions in opioid-related death rates. Health Affairs, 35, 1324–1332.CrossRef
111.
go back to reference Paulozzi, L., Kilbourne, E. M., & Desai, H. A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12, 747–754.CrossRef Paulozzi, L., Kilbourne, E. M., & Desai, H. A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12, 747–754.CrossRef
112.
go back to reference Reifler, L. M., Droz, D., Bailey, J. E., Schnoll, S. H., Fant, R., Dart, R. C., & Bucher Bartelson, B. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Medicine, 13, 434–442. Reifler, L. M., Droz, D., Bailey, J. E., Schnoll, S. H., Fant, R., Dart, R. C., & Bucher Bartelson, B. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Medicine, 13, 434–442.
113.
go back to reference Gugelmann, H. M., & Perrone, J. (2011). Can prescription drug monitoring programs help limit opioid abuse? The Journal of the American Medical Association, 306, 2258–2259.CrossRef Gugelmann, H. M., & Perrone, J. (2011). Can prescription drug monitoring programs help limit opioid abuse? The Journal of the American Medical Association, 306, 2258–2259.CrossRef
114.
go back to reference Simoni-Wastila, L., & Yang, H. K. (2006). Psychoactive drug abuse in older adults. The American Journal of Geriatric Pharmacotherapy, 4, 380–394.CrossRef Simoni-Wastila, L., & Yang, H. K. (2006). Psychoactive drug abuse in older adults. The American Journal of Geriatric Pharmacotherapy, 4, 380–394.CrossRef
115.
go back to reference Fischer, B., Lusted, A., Roerecke, M., Taylor, B., & Rehm, J. (2012). The prevalence of mental health and pain symptoms in general population samples reporting non-medical use of prescription opioids: A systematic review and meta-analysis. Journal of Pain, 13, 1029–1044.CrossRef Fischer, B., Lusted, A., Roerecke, M., Taylor, B., & Rehm, J. (2012). The prevalence of mental health and pain symptoms in general population samples reporting non-medical use of prescription opioids: A systematic review and meta-analysis. Journal of Pain, 13, 1029–1044.CrossRef
116.
go back to reference Albert, S., Brason, F. W., Sanford, C. K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Medicine (Malden, Mass.), 12(Suppl. 2), S77–S85. Albert, S., Brason, F. W., Sanford, C. K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Medicine (Malden, Mass.), 12(Suppl. 2), S77–S85.
117.
go back to reference Stewart, H., Malinowski, A., Ochs, L., Jaramillo, J., McCall, K., 3rd, & Sullivan, M. (2015). Inside Maine’s medicine cabinet: Findings from the drug enforcement administration’s medication take-back events. American Journal of Public Health, 105(1), e65–e71.CrossRef Stewart, H., Malinowski, A., Ochs, L., Jaramillo, J., McCall, K., 3rd, & Sullivan, M. (2015). Inside Maine’s medicine cabinet: Findings from the drug enforcement administration’s medication take-back events. American Journal of Public Health, 105(1), e65–e71.CrossRef
118.
go back to reference Katz, N., Adams, E. H., Chilcoat, H., Colucci, R., Comer, S. D., Goliber, P., … Weiss, R. (2007). Challenges in the development of prescription opioid abuse-deterrent formulations. Clinical Journal of Pain, 23, 648–660. Katz, N., Adams, E. H., Chilcoat, H., Colucci, R., Comer, S. D., Goliber, P., … Weiss, R. (2007). Challenges in the development of prescription opioid abuse-deterrent formulations. Clinical Journal of Pain, 23, 648–660.
119.
go back to reference Romach, M. K., Schoedel, K. A., & Sellers, E. M. (2013). Update on tamper-resistant drug formulations. Drug and Alcohol Dependence, 130, 13–23.CrossRef Romach, M. K., Schoedel, K. A., & Sellers, E. M. (2013). Update on tamper-resistant drug formulations. Drug and Alcohol Dependence, 130, 13–23.CrossRef
120.
go back to reference Mastropietro, D. J., & Omidian, H. (2013). Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Development and Industrial Pharmacy, 39, 611–624.CrossRef Mastropietro, D. J., & Omidian, H. (2013). Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Development and Industrial Pharmacy, 39, 611–624.CrossRef
121.
go back to reference Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J., Amass, L., Cooper, Z. D., … Kleber, H. D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction, 105, 709–718. Comer, S. D., Sullivan, M. A., Vosburg, S. K., Manubay, J., Amass, L., Cooper, Z. D., … Kleber, H. D. (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction, 105, 709–718.
122.
go back to reference Lavonas, E. J., Severtson, S. G., Martinez, E. M., Bucher-Bartelson, B., Le Lait, M. C., Green, J. L., … Dart, R. C. (2014). Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 47, 27–34. Lavonas, E. J., Severtson, S. G., Martinez, E. M., Bucher-Bartelson, B., Le Lait, M. C., Green, J. L., … Dart, R. C. (2014). Abuse and diversion of buprenorphine sublingual tablets and film. Journal of Substance Abuse Treatment, 47, 27–34.
123.
go back to reference Severtson, S. G., Ellis, M. S., Kurtz, S. P., Rosenblum, A., Cicero, T. J., Parrino, M. W., … Dart, R. C. (2016). Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence, 168, 219–229. Severtson, S. G., Ellis, M. S., Kurtz, S. P., Rosenblum, A., Cicero, T. J., Parrino, M. W., … Dart, R. C. (2016). Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug and Alcohol Dependence, 168, 219–229.
124.
go back to reference Bannwarth, B. (2012). Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs, 72, 1713–1723.CrossRef Bannwarth, B. (2012). Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs, 72, 1713–1723.CrossRef
125.
go back to reference Becker, W. C., & Fiellin, D. A. (2017). Abuse-deterrent opioid formulations—Putting the potential benefits into perspective. New England Journal of Medicine, 376, 2015–2103.CrossRef Becker, W. C., & Fiellin, D. A. (2017). Abuse-deterrent opioid formulations—Putting the potential benefits into perspective. New England Journal of Medicine, 376, 2015–2103.CrossRef
126.
go back to reference Cicero, T. J., & Ellis, M. S. (2015). Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin. JAMA Psychiatry, 72, 424–429.CrossRef Cicero, T. J., & Ellis, M. S. (2015). Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin. JAMA Psychiatry, 72, 424–429.CrossRef
127.
go back to reference Lourenco, L. M., Matthews, M., & Jamison, R. N. (2013). Abuse-deterrent and tamper-resistant opioids: How valuable are novel formulations in thwarting non-medical use? Expert Opinion on Drug Delivery, 10, 229–240.CrossRef Lourenco, L. M., Matthews, M., & Jamison, R. N. (2013). Abuse-deterrent and tamper-resistant opioids: How valuable are novel formulations in thwarting non-medical use? Expert Opinion on Drug Delivery, 10, 229–240.CrossRef
128.
go back to reference Butler, S. F., Cassidy, T. A., Chilcoat, H., Black, R. A., Landau, C., Budman, S. H., & Coplan, P. M. (2013). Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain, 14, 351–358. Butler, S. F., Cassidy, T. A., Chilcoat, H., Black, R. A., Landau, C., Budman, S. H., & Coplan, P. M. (2013). Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. The Journal of Pain, 14, 351–358.
129.
go back to reference Cicero, T. J., Ellis, M. S., & Surratt, H. L. (2012). Effect of abuse-deterrent formulation of OxyContin. The New England Journal of Medicine, 367(2), 187–189.CrossRef Cicero, T. J., Ellis, M. S., & Surratt, H. L. (2012). Effect of abuse-deterrent formulation of OxyContin. The New England Journal of Medicine, 367(2), 187–189.CrossRef
130.
go back to reference Coplan, P. M., Kale, H., Sandstrom, L., Landau, C., & Chilcoat, H. D. (2013). Changes in oxycodone and heroin exposures in the national poison data system after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiology and Drug Safety, 22, 1274–1282.CrossRef Coplan, P. M., Kale, H., Sandstrom, L., Landau, C., & Chilcoat, H. D. (2013). Changes in oxycodone and heroin exposures in the national poison data system after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiology and Drug Safety, 22, 1274–1282.CrossRef
131.
go back to reference Coplan, P. M., Chilcoat, H. D., Butler, S. F., Sellers, E. M., Kadakia, A., Karikrishnan, V., … Dart, R. C. (2016). The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid-abuse related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics, 100, 275–286. Coplan, P. M., Chilcoat, H. D., Butler, S. F., Sellers, E. M., Kadakia, A., Karikrishnan, V., … Dart, R. C. (2016). The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid-abuse related outcomes in the postmarketing setting. Clinical Pharmacology & Therapeutics, 100, 275–286.
132.
go back to reference Sessler, N. E., Downing, J. M., Kale, H., Chilcoat, H. D., Baumgartner, T. F., & Coplan, P. M. (2014). Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiology and Drug Safety, 23, 1238–1246.CrossRef Sessler, N. E., Downing, J. M., Kale, H., Chilcoat, H. D., Baumgartner, T. F., & Coplan, P. M. (2014). Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiology and Drug Safety, 23, 1238–1246.CrossRef
133.
go back to reference Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., & Green, J. L. (2015). Trends in opioid analgesic abuse and mortality in the United States. The New England Journal of Medicine, 372(3), 241–248. Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., & Green, J. L. (2015). Trends in opioid analgesic abuse and mortality in the United States. The New England Journal of Medicine, 372(3), 241–248.
134.
go back to reference Strang, J., & Sheridan, J. (1997). Heroin prescribing in the “British system” of the mid 1990s: Data from the 1995 national survey of community pharmacies in England and Wales. Drug and Alcohol Review, 16, 7–16.CrossRef Strang, J., & Sheridan, J. (1997). Heroin prescribing in the “British system” of the mid 1990s: Data from the 1995 national survey of community pharmacies in England and Wales. Drug and Alcohol Review, 16, 7–16.CrossRef
135.
go back to reference Surratt, H. L., O’Grady, C., Kurtz, S. P., Stivers, Y., Cicero, T. J., Dart, R. C., & Chen, M. (2014). Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiology and Drug Safety, 23, 314–320. Surratt, H. L., O’Grady, C., Kurtz, S. P., Stivers, Y., Cicero, T. J., Dart, R. C., & Chen, M. (2014). Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiology and Drug Safety, 23, 314–320.
136.
go back to reference Johnson, H., Paulozzi, L., Porucznik, C., Mack, K., & Herter, B. (2014). Decline in drug overdose deaths after state policy changes—Florida, 2010–2012. MMWR: Morbidity and Mortality Weekly Report, 63, 569–574. Johnson, H., Paulozzi, L., Porucznik, C., Mack, K., & Herter, B. (2014). Decline in drug overdose deaths after state policy changes—Florida, 2010–2012. MMWR: Morbidity and Mortality Weekly Report, 63, 569–574.
137.
go back to reference Brennan, T. A., Rothman, D. J., Blank, L., Blumenthal, D., Chimonas, S. C., Cohen, J. J., … Smelser, N. (2006). Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. The Journal of the American Medical Association, 295, 429–433. Brennan, T. A., Rothman, D. J., Blank, L., Blumenthal, D., Chimonas, S. C., Cohen, J. J., … Smelser, N. (2006). Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. The Journal of the American Medical Association, 295, 429–433.
138.
go back to reference Kassirer, J. P. (2005). On the take: How medicine’s complicity with big business can endanger your health. New York: Oxford University Press.CrossRef Kassirer, J. P. (2005). On the take: How medicine’s complicity with big business can endanger your health. New York: Oxford University Press.CrossRef
Metadata
Title
How Should the United States Respond to the Opioid Addiction and Overdose Epidemic?
Authors
Keith Humphreys
Harold A. Pollack
Copyright Year
2020
DOI
https://doi.org/10.1007/978-3-030-11908-9_10